EP2545939

BIOMARIN PHARMACEUTICAL
Application Number
EP12005352A
Filing Date
Apr 11, 2008
Status
Revoked
Jul 7, 2023
Grant Date
Dec 16, 2020
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Biblio Summary

The patent EP2545939B1 was granted on Dec 16, 2020 by Biomarin Pharmaceutical The patent is currently Revoked.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

CORIPHARMA EHFSep 16, 2021ADMISSIBLE
BETAPHARM ARZNEIMITTELSep 15, 2021ADMISSIBLE
STADA ARZNEIMITTELSep 14, 2021ADMISSIBLE
TEVA PHARMACEUTICAL INDUSTRIESSep 14, 2021WITHDRAWN
DIPHARMAJul 13, 2021WITHDRAWN

Patent citations in opposition refer to prior patents or publications that may challenge the validity of a contested patent. These references help assess whether the invention is truly novel or overlaps with existing intellectual property.

Citation PhasePatent NumberPatent LinkCited Text
OppositionUS4550109
N/A
OppositionWO2005049000
N/A
OppositionWO2006055511
N/A
OppositionWO2006034373
N/A
OppositionEP1708690
N/A
OppositionUS2006211701
N/A
OppositionWO2008128049
N/A
OppositionEP2139485
N/A

Access Full Citation Information

Get a free, in-depth citation report including examiner, opposition, and international search citations.

Get Free Citation Report

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.